Why Exact Sciences (EXAS) is a Top Momentum Stock for the Long-Term

Exact Sciences (EXAS), a molecular diagnostics company, is identified as a top momentum stock, exhibiting a 12.3% share price increase over the past four weeks. Despite its Zacks Rank #3 (Hold), EXAS holds strong 'A' ratings for both Momentum and VGM Style Scores, underpinned by four recent upward revisions to its fiscal 2025 earnings estimates, which boosted the Zacks Consensus Estimate by $0.20 to $0.36 per share, and a notable average earnings surprise of 329.9%.

Analysis

Exact Sciences (EXAS) is demonstrating significant positive momentum, underpinned by favorable analyst sentiment regarding its future earnings. The company's shares have appreciated 12.3% over the last four weeks, supporting its 'A' grade for the Momentum Style Score. This price action is corroborated by fundamental improvements in its earnings outlook, with four analysts revising their fiscal 2025 earnings estimates upward within the past 60 days. This has driven the Zacks Consensus Estimate for fiscal 2025 to increase from a previously lower figure by $0.20 to $0.36 per share. Furthermore, a historical average earnings surprise of +329.9% suggests a consistent pattern of outperforming market expectations. While these factors are strongly bullish, they are contrasted by the stock's neutral Zacks Rank of #3 (Hold). However, a composite VGM Score of 'A' indicates that despite the neutral overall rank, the stock's combined value, growth, and momentum characteristics are considered highly attractive.

Key Decisions for Investors

• Momentum-focused investors should consider the strong technical signal of a 12.3% price increase and the fundamental support from upward revisions in FY2025 earnings estimates as a potentially favorable entry point.
• Investors should weigh the positive momentum indicators and strong 'A' rated style scores against the neutral #3 'Hold' rank, which may imply that the stock is currently fairly valued or that other unstated factors are tempering the overall outlook.
• Given the thesis is heavily based on analyst revisions, it is critical to monitor upcoming earnings reports and subsequent estimate changes to validate if the trend of significant earnings surprises and positive revisions persists.